Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention ("The ELIMIT Trial")
Brief Summary: Peripheral arterial disease (PAD) occurs when arteries become narrowed or hardened because of a build-up of plaque or fat deposits. PAD develops most often in arteries in the legs, which can result in reduced blood flow to the legs and feet, occasionally causing leg pain and fatigue. Early identification of PAD and treatment with lifestyle changes or medications can help to keep legs healthy and lower risk for heart attack and stroke, but endovascular or surgical procedures may be necessary for people with severe PAD. Even after endovascular intervention, PAD symptoms must be continually monitored to prevent the development and progression of blockages in the arteries. The best approach for monitoring symptoms is still undetermined. This study will compare the effectiveness of an intensive combination of lipid modifying medications versus standard lipid modifying medications in treating people with significant PAD who have had an endovascular intervention.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe, Drug: Niaspan, Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Procedure: Percutaneous transluminal angioplasty (PTA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Drug: Placebo Niaspan, Drug: Placebo Ezetimibe, Procedure: Percutaneous transluminal angioplasty (PTA) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Niaspan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo Niaspan; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Ezetimibe; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Percutaneous transluminal angioplasty (PTA); Assigned to Arm(s): 1, 2
B: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Doubling statin dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin 40 mg or atorvastatin 20 mg, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): Ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin 40 mg or atorvastatin 20 mg; Assigned to Arm(s): Doubling statin dose | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: atorvastatin 10 mg or simvastatin 20 mg; Assigned to Arm(s): Doubling statin dose, Ezetimibe/simvastatin, Rosuvastatin

Answer: A